Trials / Completed
CompletedNCT05656443
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,246 (actual)
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GST-HG171/Ritonavir | dose of 150 mg GST-HG171 with 100 mg ritonavir |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-12-19
- Primary completion
- 2023-05-31
- Completion
- 2023-07-14
- First posted
- 2022-12-19
- Last updated
- 2023-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05656443. Inclusion in this directory is not an endorsement.